T. Rowe Price Associates
CDMO

T. Rowe Price Associates’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

T. Rowe Price Associates’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,753
Closed -$454K – 3100
2024
Q4 		$454K Buy
36,753
+3,427
+10% +$39.3K ﹤0.01% 2328
2024
Q3 		$380K Buy
33,326
+294
+0.9% +$2.95K ﹤0.01% 2371
2024
Q2 		$236K Buy
33,032
+2,733
+9% +$20.9K ﹤0.01% 2527
2024
Q1 		$204K Buy
30,299
+1,649
+6% +$11.3K ﹤0.01% 2619
2023
Q4 		$187K Buy
28,650
+2,535
+10% +$16.3K ﹤0.01% 2567
2023
Q3 		$247K Buy
26,115
+1,367
+6% +$16.5K ﹤0.01% 2421
2023
Q2 		$346K Buy
24,748
+872
+4% +$14.9K ﹤0.01% 2302
2023
Q1 		$448K Buy
23,876
+693
+3% +$11.4K ﹤0.01% 2160
2022
Q4 		$319K Buy
23,183
+1,009
+5% +$15.5K ﹤0.01% 2348
2022
Q3 		$424K Buy
22,174
+3,885
+21% +$70.8K ﹤0.01% 2211
2022
Q2 		$279K Buy
18,289
+400
+2% +$5.92K ﹤0.01% 2475
2022
Q1 		$364K Buy
17,889
+1,442
+9% +$29.4K ﹤0.01% 2471
2021
Q4 		$480K Buy
+16,447
New +$471K ﹤0.01% 2398

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's CDMO Position: Q1 2025 in Review

T. Rowe Price Associates sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 36,753 shares — an estimated $454K sold.

T. Rowe Price Associates first reported a position in CDMO in Q4 2021 and held it in 13 quarters. The position peaked at $480K in Q4 2021. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • T. Rowe Price Associates reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 36,753 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $454K.
  • T. Rowe Price Associates first reported a position in Avid Bioservices, Inc. Common Stock in Q4 2021 and held it in 13 quarters.
  • T. Rowe Price Associates's Avid Bioservices, Inc. Common Stock position peaked at $480K in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.